文献速递产科母胎医学

子痫前期的整合模型:母体心血管-胎盘-胎儿多维综合征

An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array.
PubMed 文献 · Am J Obstet Gynecol · 2021-03-09

本文综述提出子痫前期是母体心血管系统、胎盘与胎儿相互作用失调的多维综合征,而非单一胎盘或心脏起源。胎盘浅着床与螺旋动脉重塑不足是标志,但母体血流动力学适应不良及血管生成失衡同样关键,整合模型有助于预防、预测与治疗策略。

要点

  • 子痫前期是母体心血管-胎盘-胎儿多维网络失调的综合征。
  • 胎盘浅着床与螺旋动脉重塑不足是子痫前期标志,但非唯一决定因素。
  • 血管生成-抗血管生成失衡参与正常适应与子痫前期病理过程。

核心结论

  • 子痫前期应被视为母体心血管-胎盘-胎儿阵列整合模型下的多维综合征,任一组件或连接异常均可致病。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确报告。

主要发现

  • 胎盘浅着床伴螺旋动脉重塑不足是子痫前期标志。
  • 子宫动脉阻力缺乏正常下降可预测子痫前期。
  • 腹腔妊娠无螺旋动脉重塑但子宫动脉及眼动脉等远端血管阻力降低。
  • 母体血流动力学适应不良与子痫前期变化类似心脏病状态。
  • 胎盘生长因子与可溶性fms样酪氨酸激酶-1失衡参与子痫前期病理。

关键数值与推荐

  • 胎盘生长因子与可溶性fms样酪氨酸激酶-1的血管生成-抗血管生成平衡对正常适应重要,其失衡与子痫前期相关。

临床怎么用

  • 预防策略可包括阿司匹林治疗。
  • 预测与监测可通过母体血流动力学研究或血清胎盘生长因子与可溶性fms样酪氨酸激酶-1检测。
  • 潜在治疗可包括RNAi疗法对抗胎盘过量产生的可溶性fms样酪氨酸激酶-1。

局限性

  • 摘要未报告综述的检索范围与纳入标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Maternal tolerance of the semiallogenic fetus necessitates conciliation of competing interests. Viviparity evolved with a placenta to mediate the needs of the fetus and maternal adaptation to the demands of pregnancy and to ensure optimal survival for both entities. The maternal-fetal interface is imagined as a 2-dimensional porous barrier between the mother and fetus, when in fact it is an intricate multidimensional array of tissues and resident and circulating factors at play, encompassing the developing fetus, the growing placenta, the changing decidua, and the dynamic maternal cardiovascular system. Pregnancy triggers dramatic changes to maternal hemodynamics to meet the growing demands of the developing fetus. Nearly a century of extensive research into the development and function of the placenta has revealed the role of placental dysfunction in the great obstetrical syndromes, among them preeclampsia. Recently, a debate has arisen questioning the primacy of the placenta in the etiology of preeclampsia, asserting that the maternal cardiovascular system is the instigator of the disorder. It was the clinical observation of the high rate of preeclampsia in hydatidiform mole that initiated the focus on the placenta in the etiology of the disease. Over many years of research, shallow trophoblast invasion with deficient remodeling of the maternal spiral arteries into vessels of higher capacitance and lower resistance has been recognized as hallmarks of the preeclamptic milieu. The lack of the normal decrease in uterine artery resistance is likewise predictive of preeclampsia. In abdominal pregnancies, however, an extrauterine pregnancy develops without remodeling of the spiral arteries, yet there is reduced resistance in the uterine arteries and distant vessels, such as the maternal ophthalmic arteries. Proponents of the maternal cardiovascular model of preeclampsia point to the observed maternal hemodynamic adaptations to pregnancy and maladaptation in gestational hypertension and preeclampsia and how the latter resembles the changes associated with cardiac disease states. Recognition of the importance of the angiogenic-antiangiogenic balance between placental-derived growth factor and its receptor soluble fms-like tyrosine kinase-1 and disturbance in this balance by an excess of a circulating isoform, soluble fms-like tyrosine kinase-1, which competes for and disrupts the proangiogenic receptor binding of the vascular endothelial growth factor and placental-derived growth factor, opened new avenues of research into the pathways to normal adaptation of the maternal cardiovascular and other systems to pregnancy and maladaptation in preeclampsia. The significance of the "placenta vs heart" debate goes beyond the academic: understanding the mutuality of placental and maternal cardiac etiologies of preeclampsia has far-reaching clinical implications for designing prevention strategies, such as aspirin therapy, prediction and surveillance through maternal hemodynamic studies or serum placental-derived growth factor and soluble fms-like tyrosine kinase-1 testing, and possible treatments to attenuate the effects of insipient preeclampsia on women and their fetuses, such as RNAi therapy to counteract excess soluble fms-like tyrosine kinase-1 produced by the placenta. In this review, we will present an integrated model of the maternal-placental-fetal array that delineates the commensality among the constituent parts, showing how a disruption in any component or nexus may lead to the multifaceted syndrome of preeclampsia.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Yagel S, Cohen SM, Goldman-Wohl D, et al. An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array. Am J Obstet Gynecol. 2021. PMID: 33712272. doi:10.1016/j.ajog.2020.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。